Eliteimmune And Integrated Biotherapeutics Enter Into Collaborative Research To Combat Methicillin-Resistant Staphylococcus Aureus (MRSA).
GAITHERSBURG, MARYLAND June 1, 2022--- Eliteimmune has entered into a collaborative research agreement with Integrated Biotherapeutics (IBT) to identify and characterize novel monoclonal antibodies to Staphylococcus aureus (S. aureus) for therapeutic, and diagnostic use. The two companies have extensive expertise in bacterial toxins, antibody discovery, vaccines, and therapeutics.
Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that colonies humans and domestic animals. S. aureus is responsible for a variety is diseases such as skin and soft tissue infections, endocarditis, osteomyelitis, bacteremia, food poisoning, toxic shock syndrome, and lethal pneumonia S. aureus produces over 20 different toxins which include Enterotoxin A and B (SEA and SEB), alpha-toxin (Hla), Panton-Valentine leucocidin (PVL), and toxic shock syndrome toxin (TSST). In recent decades, there has been a dramatic increase the prevalence of drug resistance S. aureus, also known as methicillin-resistant Staphylococcus aureus (MRSA). The alarming rate of outbreaks associated with drug resistance bacteria underscores the urgency for research to identify novel therapeutics to combat disease.
About Eliteimmune: Eliteimmune is an industry leader in the discovery and characterization of antibody therapeutics for infectious disease, oncology and aging. Eliteimmune’s pipeline includes the development of Ebola, HBV, HCV, RSV and anti-tumor TCR monoclonal antibodies. Eliteimmune’s RSV therapeutic antibody is currently in Phase I clinical trials. Eliteimmune seeks collaborations with government, academic and biotechnology agencies. To learn more, please visit us at www.eliteimmune.com
About Integrated Biotherapeutics: IBT develops vaccines and immunotherapies for bacterial and viral infectious diseases. The Company's lead vaccine product, IBT-V02 is a first-in-class multi-component vaccine against Staphylococcus aureus. Supported by CARB-X and by Novo Holdings' Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies, with initiation of clinical trials anticipated in late 2021. IBT's portfolio also includes novel monoclonal antibody therapeutics for Ebola and Marburg viruses. Learn more about IBT's pipeline at www.integratedbiotherapeutics.com.
###
Contact:
Eliteimmune, Corp
Katie Howell, Ph.D. Business Development Manager
info@eliteimmune.com
www.eliteimmune.com
